Turkish Abstract Abstract Free Full Text English Similar Articles Mail to Author

¹MD, Saint Louis University, Department of Ophthalmology, St. Louis, MO, USA
²MD, Adjunct Professor of Ophthalmology, Saint Louis University, Department of Ophthalmology
³MD, Eye Care Partners, LLC
⁴MD, The Retina Center, PC, St. Louis, MO, USA DOI : 10.37845/ret.vit.2020.29.52 Brolucizumab is the newest anti-vascular endothelial growth factor (anti-VEGF) drug approved for use. The aim of this review is to review the HAWK/HARRIER clinical trials, examine post-marketing experience with the drug, and evaluate the packaging/procedural differences with brolucizumab. Brolucizumab is a more potent and longer lasting anti-VEGF agent, and is an important agent that may be used in the treatment of neovascular age-related macular degeneration. Retinal vasculitis is a rare but very serious complication of brolucizumab that the patient and physician must be aware of. Keywords : Brolucizumab, VEGF